Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
grade F 5.33 0.38% 0.02
CERS closed up 0.38 percent on Friday, September 20, 2019, on approximately normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CERS trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Support Bullish 0.38%
Bollinger Band Squeeze Range Contraction 0.38%
20 DMA Support Bullish 0.57%
Narrow Range Bar Range Contraction 0.57%
NR7 Range Contraction 0.57%
Inside Day Range Contraction 0.57%

Older signals for CERS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Anatomy Blood Transfusion Medicine Hematology Blood Products Coagulation System Blood Transfusion Platelet Red Blood Cell
Is CERS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.54
52 Week Low 4.485
Average Volume 809,081
200-Day Moving Average 5.6348
50-Day Moving Average 5.3992
20-Day Moving Average 5.2475
10-Day Moving Average 5.269
Average True Range 0.1959
ADX 14.06
+DI 20.6778
-DI 15.7455
Chandelier Exit (Long, 3 ATRs ) 4.9723
Chandelier Exit (Short, 3 ATRs ) 5.3977
Upper Bollinger Band 5.4852
Lower Bollinger Band 5.0098
Percent B (%b) 0.67
BandWidth 9.059552
MACD Line -0.0085
MACD Signal Line -0.0287
MACD Histogram 0.0203
Fundamentals Value
Market Cap 581.69 Million
Num Shares 109 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -8.74
Price-to-Sales 8.39
Price-to-Book 7.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.53
Resistance 3 (R3) 5.51 5.43 5.49
Resistance 2 (R2) 5.43 5.38 5.44 5.48
Resistance 1 (R1) 5.38 5.35 5.41 5.40 5.47
Pivot Point 5.30 5.30 5.31 5.31 5.30
Support 1 (S1) 5.25 5.25 5.28 5.27 5.19
Support 2 (S2) 5.17 5.22 5.18 5.18
Support 3 (S3) 5.12 5.17 5.17
Support 4 (S4) 5.14